REYON Pharmaceutical Co., Ltd. (KRX: 102460)

Market Cap	234.03B
Revenue (ttm)	149.84B
Net Income (ttm)	615.80M
Shares Out	18.34M
EPS (ttm)	33.20
PE Ratio	380.05
Forward PE	n/a
Dividend	150.00 (1.18%)
Ex-Dividend Date	Dec 27, 2024

Volume	4,992
Open	12,800
Previous Close	13,310
Day's Range	12,770 - 12,820
52-Week Range	11,170 - 18,650
Beta	1.00
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 12, 2025

About REYON Pharmaceutical

REYON Pharmaceutical Co., Ltd. manufactures and sells medicines. The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; antibiotics; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough and cold remedies; cardiac stimulant; genitourinary smooth muscle relaxants; hemostatics; immunosuppressants; rheumatoid arthritis; local anesthetics; ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1955
• Employees: 448
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 102460

Financial Performance

In 2023, REYON Pharmaceutical's revenue was 151.07 billion, a decrease of -1.93% compared to the previous year's 154.04 billion. Earnings were 3.58 billion, a decrease of -51.30%.